Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cisplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of cetuximab (an EGFR inhibitor monoclonal antibody), cisplatin (a platinum-based chemotherapeutic agent), 5-fluorouracil (a pyrimidine analog), and leucovorin (a reduced folate that enhances 5-FU activity). This regimen is primarily used for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). A modified bi-weekly administration schedule has been developed to reduce hospitalization time and chemotherapy exposure while maintaining efficacy.
- Other names
- FPE therapyModified EXTREME protocol
02
Targets
Beyond the preview
Go deeper on cetuximab + cisplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cisplatin + 5-fluorouracil + leucovorin.